40Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Ireland
Neuroscience Intelligence
Ireland neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #35 of 50 · Data maturity A · Research score 31.2 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
13Recruiting trials
106Publications
40Institutions
Executive interpretation
Ireland ranks #35 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC125 recruiting
Novo Nordisk A/S20 recruiting
Royal College of Surgeons, Ireland20 recruiting
Boehringer Ingelheim10 recruiting
Eli Lilly and Company10 recruiting
FUJIFILM Toyama Chemical Co., Ltd.10 recruiting
Eidos Therapeutics, a BridgeBio company11 recruiting
Health Service Executive, Ireland11 recruiting
Heidelberg University11 recruiting
Friedreich's Ataxia Research Alliance11 recruiting
Disease activity
Parkinsons13trials
Alzheimers6trials
Epilepsy5trials
Stroke4trials
Multiple Sclerosis3trials
Adhd2trials
Other Neurology2trials
Traumatic Brain Injury1trials
Autism1trials
Schizophrenia1trials
Research institutions
Raidió Teilifís Éireann (Ireland)OpenAlexlinked institution
Munster Technological UniversityOpenAlexlinked institution
Science Foundation IrelandOpenAlexlinked institution
Children's Health Ireland at CrumlinOpenAlexlinked institution
National Maternity HospitalOpenAlexlinked institution
Institute of Technology TraleeOpenAlexlinked institution
Rotunda HospitalOpenAlexlinked institution
University of LimerickOpenAlexlinked institution
University Hospital GalwayOpenAlexlinked institution
Insight SFI Research Centre for Data AnalyticsOpenAlexlinked institution
Clinical evidence trail
NCT07798674TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic AtaxiasRECRUITING
NCT07310914Implementation of an Advanced Telerehabilitation Solution for People With Multiple SclerosisNOT_YET_RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRECRUITING
NCT05269394Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)ACTIVE_NOT_RECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)ACTIVE_NOT_RECRUITING
NCT05064878A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.ACTIVE_NOT_RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
Research evidence trail
PUBMEDPersonalized whole-body modeling links gut microbiota to metabolic perturbations in Alzheimer's disease.2026-12-31
PUBMEDUnravelling the role of the gut microbiome in antipsychotic-induced weight gain and metabolic dysfunction in humans and rodents: A systematic review.2026-12-01
PUBMEDStructural Brain Network Alterations in Relation to Treatment and Illness Severity in Bipolar Disorder.2026-11-15
PUBMEDNeurotransmitter-Defined Degeneration Patterns in Sporadic and C9orf72-Associated Amyotrophic Lateral Sclerosis: Predilection to GABAergic, Serotonergic, Opioid, Glutamatergic, Endocannabinoid, and Microglial Systems-Implications for Therapy Development.2026-11-01
PUBMEDSpeech and swallow outcome measures for ALS and perspectives on remote monitoring: an international survey of speech & language therapists.2026-11-01
PUBMEDLongitudinal associations between family factors and the neurodevelopmental and psychosocial outcomes of children with congenital heart disease: A systematic review.2026-11-01
PUBMEDBrain health strategies in middle-aged individuals with mild neurocognitive disorder: a scoping review.2026-11-01
PUBMEDRe-evaluating response rates, time to reorientation and inadequate seizure duration in magnetic seizure therapy for schizophrenia and major depression.2026-11-01
PUBMEDBiomarkers of Subjective Tinnitus Presence and Clinical Burden: A Systematic Review.2026-11-01
PUBMEDDiagnostic and mechanistic insights from molecular profiling of explanted stereo-EEG depth electrodes.2026-10-23
PUBMEDNon-invasive neuromodulation after repetitive head impacts: current evidence and a precision framework for circuit-based rehabilitation.2026-10-22
PUBMEDCaffeine attenuates Aβ-induced hippocampal dysfunction alongside changes in adenosine receptor-linked GABA handling and neuronal excitability.2026-10-21
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.